These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 17206389)

  • 41. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus.
    Davidson M; Meyer PM; Haffner S; Feinstein S; D'Agostino R; Kondos GT; Perez A; Chen Z; Mazzone T
    Circulation; 2008 Apr; 117(16):2123-30. PubMed ID: 18413496
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dyslipidaemia in diabetic patients: time for a rethink.
    Shepherd J
    Diabetes Obes Metab; 2007 Sep; 9(5):609-16. PubMed ID: 17697054
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Frequency of lipid-lowering drug therapy after coronary and carotid operations for atherosclerosis.
    Roberts CS; Donovan KD; McCarthy PJ; Keagy BA
    South Med J; 2000 Apr; 93(4):424-6. PubMed ID: 10798514
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The benefit of statins in non-cardiac vascular surgery patients.
    Stalenhoef AF
    J Vasc Surg; 2009 Jan; 49(1):260-5. PubMed ID: 19174265
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chemoprevention of coronary atherosclerosis: the role of lipid interventions. A position paper of the American Council on Science and Health.
    LaRosa JC
    MedGenMed; 2002 Mar; 4(1):12. PubMed ID: 11965214
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects on coronary atherosclerosis by targeting low-density lipoprotein cholesterol with statins.
    Ferrières J
    Am J Cardiovasc Drugs; 2009; 9(2):109-15. PubMed ID: 19331439
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lipid changes and statins in chronic renal insufficiency.
    Ritz E; Wanner C
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S226-30. PubMed ID: 17130266
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New options in lipid management--can we extend the benefits of current therapy? Introduction.
    Gotto AM; Paoletti R
    Am Heart J; 2002 Dec; 144(6 Suppl):S19-20. PubMed ID: 12486411
    [No Abstract]   [Full Text] [Related]  

  • 49. Cholesterol, lipids, and statins.
    Ballantyne CM
    Tex Heart Inst J; 2005; 32(3):378-9. PubMed ID: 16392223
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Optimal lipids, statins, and dementia.
    Lavie CJ; Milani RV
    J Am Coll Cardiol; 2005 Mar; 45(6):963-4; author reply 964-5. PubMed ID: 15766838
    [No Abstract]   [Full Text] [Related]  

  • 51. Carotid atherosclerotic plaque stenosis: the stabilizing role of statins.
    Artom N; Montecucco F; Dallegri F; Pende A
    Eur J Clin Invest; 2014 Nov; 44(11):1122-34. PubMed ID: 25231921
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High dose statin therapy for all patients with coronary artery disease?
    Knobler H
    Isr Med Assoc J; 2005 Nov; 7(11):736-8. PubMed ID: 16308999
    [No Abstract]   [Full Text] [Related]  

  • 53. Recent trials of lipid lowering.
    Ray KK; Cannon CP; Braunwald E
    Int J Clin Pract; 2007 Jul; 61(7):1145-59. PubMed ID: 17577297
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Candidate mechanisms for regression of coronary atherosclerosis with high-dose statins: insight from intravascular ultrasonography trials.
    Sipahi I; Tuzcu EM
    Am J Cardiovasc Drugs; 2008; 8(6):365-71. PubMed ID: 19159123
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treating to goal: new strategies for initiating and optimizing lipid-lowering therapy in patients with atherosclerosis.
    Fonarow GC;
    Vasc Med; 2002 Aug; 7(3):187-94. PubMed ID: 12553742
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Statins and regression of coronary atherosclerosis.
    Athyros VG; Kakafika A; Karagiannis A; Mikhailidis DP
    JAMA; 2007 May; 297(20):2197; author reply 2197. PubMed ID: 17519408
    [No Abstract]   [Full Text] [Related]  

  • 57. Pathophysiology, diagnosis, and management of dyslipidemia.
    Gau GT; Wright RS
    Curr Probl Cardiol; 2006 Jul; 31(7):445-86. PubMed ID: 16824902
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment Study (HATS), Armed Forces Regression Study (AFREGS), and Carotid Plaque Composition by MRI during lipid-lowering (CPC) study.
    Phan BA; Muñoz L; Shadzi P; Isquith D; Triller M; Brown BG; Zhao XQ
    Am J Cardiol; 2013 Feb; 111(3):352-5. PubMed ID: 23168285
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevention and regression of atherosclerosis: effects of HMG-CoA reductase inhibitors.
    Bjelajac A; Goo AK; Weart CW
    Ann Pharmacother; 1996 Nov; 30(11):1304-15. PubMed ID: 8913414
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical value of drugs targeting inflammation for the management of coronary artery disease.
    Duchatelle V; Kritikou EA; Tardif JC
    Can J Cardiol; 2012; 28(6):678-86. PubMed ID: 22926034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.